» » Biotechnology Valuation: An Introductory Guide

Download Biotechnology Valuation: An Introductory Guide fb2

by Karl Keegan
Download Biotechnology Valuation: An Introductory Guide fb2
Investing
  • Author:
    Karl Keegan
  • ISBN:
    0470511788
  • ISBN13:
    978-0470511787
  • Genre:
  • Publisher:
    Wiley; 1 edition (December 31, 2008)
  • Pages:
    218 pages
  • Subcategory:
    Investing
  • Language:
  • FB2 format
    1841 kb
  • ePUB format
    1884 kb
  • DJVU format
    1548 kb
  • Rating:
    4.1
  • Votes:
    614
  • Formats:
    docx rtf mbr lrf


Written by experienced financial analyst, Karl Keegan, Biotechnology Valuation: An Introductory Guide is a hands-on guide to the valuation of biotechnology companies both from a private and public market perspective for industry professionals, investors and students

Written by experienced financial analyst, Karl Keegan, Biotechnology Valuation: An Introductory Guide is a hands-on guide to the valuation of biotechnology companies both from a private and public market perspective for industry professionals, investors and students. Focused on product based biotechnology investments and drawing on the author’s extensive experience the book begins by valuing healthcare focussed biotechnology companies which are trying to develop new therapeutics using traditional valuation metrics for those readers unfamiliar with finance. The book then takes these principles.

Praise for Biotechnology Valuation. Keegan states that the valuation of Biotech companies is as much an art as a science. Biotech investing is not for the timid, but it can bring substantial returns.

Praise for Biotechnology Valuation Keegan's book, punctuated with his personal experience and opinions, is a. . Keegan's book, punctuated with his personal experience and opinions, is a good place to start. Karl has been a financial analyst covering the biotechnology sector for over eleven years and has previously worked at Dresdner Kleinwort Benson, UBS and Banc of America.

Dr Keegan's book is a fine resource for both business types and academicians.

Request PDF Biotechnology Valuation: An Introductory Guide The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology. Dr Keegan's book is a fine resource for both business types and academicians.

The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and.

Biotechnology valuation : an introductory guide, Karl D. Keegan. This book should provide a background to the principles of valuation and a toolkit to establishing the value of a biotechnology company

Biotechnology valuation : an introductory guide, Karl D. p. cm. Includes bibliographical references and index. This book should provide a background to the principles of valuation and a toolkit to establishing the value of a biotechnology company.

Unit - 11 Biotechnology basics: Genetic engineering, culture media, The present book entitled. Printed and bound in the UK by MPG Books Group History of Biotechnology, Genetics and Selective 9781845936518. Enzymes: Biochemistry, Biotechnology, Clinical Chemistry. Applied Molecular Biotechnology: The Next Generation of Genetic Engineering. 96 MB·7,175 Downloads. Chapter 3 Plant molecular biotechnology: Applications of transgenics. Muhammad Applied Molecular Biotech. introduction to biotechnology and genetic engineering.

Author: Keegan, Karl. This book provides a thorough introduction to the business and valuation of Biotechnology stocks for investors. Full Text Information. Publication Date:2009-01-14. ISBN-13:9780470511787. Number of Pages:218 Pages. It offers a brief history of the Biotechnology industry and the investment waves and dips over the last 30 years of the industry. It examines both the .

The first book to provide a simple and practical means ofvaluing biotech companiesThe book begins with a short history of the biotechnologyindustry; this is important as although it is about 30 years old,the first company went public only in 1996, so it is possible toplot the course of investment waves and dipsIt examines the European industry and its evolvement, and drawsparallels between the similarities and differences between that andthe USLooks at the various companies which make up the biotechindustry (therapeutic; life sciences; and the medical technologycompany) and gives tools for the investor to properly evaluatethemPraise for Biotechnology Valuation

"Keegan states that the valuation of Biotech companies is asmuch an art as a science. This brief but comprehensive review ofthe skills and knowledge required, not of just the financial marketand sentiment, but also of the technical attributes of a companyand the drug development and regulatory hurdles that must beovercome, highlights the importance of the breadth of understandingrequired. Biotech investing is not for the timid, but it can bringsubstantial returns. Keegan's book, punctuated with his personalexperience and opinions, is a good place to start."—Chris Blackwell, Chief Executive, Vectura Groupplc

"A user-friendly, yet thorough discussion of a notoriouslydifficult topic. Dr Keegan's book is a fine resource for bothbusiness types and academicians."—Steve Winokur, Managing Director, CanaccordAdams

"A highly readable and comprehensive explanation of thetechnical and commercial parameters that influence biotechnologycompanies at all stages of development, providing clear context forselection from the toolkit of valuation methodologies the authorrecommends to assess company and product performance, or ascribevalue."—Dr L.M. Allan, Director, Bioscience EnterpriseProgramme, University of Cambridge

"A fabulous approach to a difficult topic."—Deirdre Y. Gillespie, MD, President & CEO, LaJolla Pharmaceutical Company


Bloodfire
I believe Keegan in his book Biotechnology Valuation was just looking for a quick dollar when writing this book. Throughout his book he skims over sections without giving the reader any justification as to why he's making certain assumptions (i.e. taking the NPV of peak sales versus summing the projected NPV of sales over a ten year period). There are also quite a few little mistakes that can make this book a little more difficult to read such as spelling mistakes and misplaced references (i.e. he refers to a table-set that isn't there). So to sum up, this is a decent book for someone with no experience in valuation, but there are many other books for valuation that are much better, as far as biotech is concerned, most of the information in here can be found on the internet at no cost. Definitely wouldn't buy this book again...
Joni_Dep
Dr. Keegan offers an excellent introduction to the complex task of valuing companies based on biotechnology. His clear and succinct style aids the reader in breaking the problem down into its most important drivers. Furthermore, Dr. Keegan outlines the critical, rational assumptions required during this process, without which, one would be hopelessly lost. I highly recommend this book to both the amateur and professional investor, as well as anyone involved in the biotechnology industry.
Dorilune
Keegan tries his best with a very difficult subject. The fundamental problem is, as he says, "there is no obvious or accepted way of applying valuation in the biotechnology industry". It has to do with the complexity of the designed drugs or therapies, and the complexity of responses from a set of human test subjects.

Given these hurdles, the book does an admirable job. Keegan gamely walks us through how the Capital Asset Pricing Model (CAPM) might be applied to a biotech, in no small way to get a Net Present Value. A decision tree method is given, that might prove useful to some biotechs.

His analysis cannot be faulted, so long as you always keep in mind the assumptions upfrontly presented in the text.
Deodorant for your language
Can be used as a "Biotech Investing 101" book. However readers should note that the book has full of errors on some important concepts (yes I'm talking about the discount factor and NPV, I spent a hell amount of time figuring out which his summary tables were correct because they contradict each other). I was so surprised how the book got passed the editors. And does the writer even proofread himself?
Isha
Typographical errors aside, there are formulaic errors as well (e.g. terminal value equation for perpetuity with growth). It's like this guy tried to intuitively figure stuff out but copied formulae incorrectly from the web. Not very useful as an introduction because the concepts he does cover are trivial and the ones he glosses over are the very concepts that an introduction ought to explore deeper (e.g. debt, beta, unlevering); precisely what someone who doesn't really know what they're talking about would do: duck and weave around topics that he does not fully understand and for which he has cobbled together some flimsy patchwork intuition. In a conversation, Keegan would fold like a deck chair in a hurricane. Pass.
Xaluenk
Do not buy this book. It is a complete waste of money, riddled with mistakes, inaccuracies, confusing layouts, and terrible grammar. You will hard pressed to find a single comma, or equation that makes sense to someone who doesn't have extensive experience with finance.

To MBE students - the author's lectures are as confusing as his book, and I recommend avoiding this like the plague. I am a former MBE student and can guarantee that everyone on the course who bought it was very upset with it.